Edesa Biotech enters $3.87M ATM equity facility with H.C. Wainwright; terminates prior Canaccord agreement

Edesa Biotech, Inc.

Entered ATM agreement with H.C. Wainwright to sell up to $3.87M common shares at market prices; commission 3%.
Terminated prior equity distribution agreement with Canaccord Genuity (dated March 2023) effective Oct 3, 2024.
Under the Canaccord agreement, Edesa sold ~368,309 shares for ~$2.0M proceeds; no termination penalties.
No obligation to sell all shares under the new ATM; company may suspend sales at any time.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.